Therapy optimization in patients with heart failure: the role of the wearable cardioverterd-efibrillator in a real-world setting
Therapy optimization in patients with heart failure: the role of the wearable cardioverterd-efibrillator in a real-world setting
复制标题
DOI：
10.1186/s12872-018-0790-8
复制
发表时间：
2018-03-15
影响因子：
2.1
通讯作者：
Borggrefe, Martin
中科院分区：
文献类型：
--
作者：
Roeger, Susanne;Rosenkaimer, Stefanie L.;Borggrefe, Martin
背景资料：可穿戴心律转复除颤器（WCD）已成为一种有价值的工具，以暂时保护患者的心脏性猝死（SCD）的风险。本研究的目的是确定WCD对心力衰竭患者治疗优化的价值。方法：本研究纳入了105名在2012年4月至2016年9月期间接受WCD的连续患者。结果：WCD最常见的适应症是新诊断的缺血性心肌病（ICM）或非缺血性心肌病（NICM），左室射血分数（LVEF）为1.5%。
Background: The wearable cardioverter-defibrillator (WCD) has emerged as a valuable tool to temporarily protect patients at risk for sudden cardiac death (SCD). The aim of this study was to determine the value of the WCD for therapy optimization of heart failure patients.Methods: One hundred five consecutive patients that received WCD between 4/2012 and 9/2016 were included in the study. All patients were followed for clinical outcome and echocardiographic parameters during WCD therapy and had continued follow-up after WCD therapy, irrespective of subsequent implantable cardioverter-defibrillator (ICD) implantation.Results: The most common indication for WCD were newly diagnosed ischemic (ICM) or non-ischemic cardiomyopathy (NICM) with left ventricular ejection fraction (LVEF)